GlassScriptPhysician profile
Eugene S Han
NPI 1164780797
$4,620.33
in general payments reported to CMS, 2019-2025
33 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.52 · 2020: $13.64 · 2021: $303 · 2022: $906 · 2023: $1,133 · 2024: $973 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $46.49 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.63 |
| Education | $46.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.97 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.98 | 2021-2024 | Trulance, Xifaxan, Plenvu |
| Celgene Corporation | $406.57 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $348.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $343.09 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $267.70 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $252.32 | 2022-2023 | |
| Pfizer INC. | $193.64 | 2023-2025 | |
| Genzyme Corporation | $157.40 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $153.06 | 2022-2025 | Ocaliva |
| Celltrion USA INC. | $117.27 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Boston Scientific Corporation | $81.14 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Ardelyx, INC. | $80.46 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $73.05 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $71.50 | 2022-2025 | Sutab, Suflave |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.25 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $48.23 | 2025 | |
| Daiichi Sankyo INC. | $47.65 | 2022-2023 | Injectafer |
| Olympus America INC. | $45.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $39.79 | 2024-2025 | Voquezna |
| Capsovision, INC. | $31.58 | 2023-2025 | Capsocam Plus |
| Qol Medical, LLC | $29.86 | 2021-2022 | |
| Biocon Biologics INC | $20.65 | 2025 | Yesintek |
| W. L. Gore & Associates, INC. | $20.44 | 2022 | |
| Sanofi US Services INC. | $20.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.54 | 2025 | Iqirvo |
| Organon LLC | $17.00 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.72 | 2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $14.97 | 2022 | |
| Allergan, INC. | $14.52 | 2019 | |
| Endo Pharmaceuticals INC. | $13.17 | 2023 | Nascobal |
| Micro-Tech Endoscopy USA, INC. | $8.49 | 2023 | Dilation (Need Marketed Name of Device(S), Eus Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.